Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Frequency Therapeutics Inc (FREQ)

Frequency Therapeutics Inc (FREQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,942
  • Shares Outstanding, K 36,521
  • Annual Sales, $ 0 K
  • Annual Income, $ -81,580 K
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.24
Trade FREQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.30 on 08/10/23
  • Latest Earnings Date 11/14/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +181,736.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1830 +63.72%
on 10/30/23
0.3760 -20.32%
on 10/04/23
-0.0575 (-16.10%)
since 10/03/23
3-Month
0.1830 +63.72%
on 10/30/23
0.7400 -59.51%
on 08/15/23
-0.3574 (-54.40%)
since 08/03/23
52-Week
0.1830 +63.72%
on 10/30/23
5.5900 -94.64%
on 01/24/23
-2.0404 (-87.20%)
since 11/03/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, PRDS, FREQ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AEL : 55.14 (-0.20%)
DEN : 88.66 (-0.26%)
PRDS : 2.16 (unch)
FREQ : 14.9800 (+5.94%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AJX : 3.40 (-2.02%)
DEN : 88.66 (-0.26%)
FREQ : 14.9800 (+5.94%)
NLTX : 13.96 (+1.45%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAIC, BG, DEN, FREQ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AAIC : 4.84 (+1.47%)
BG : 106.51 (+1.03%)
DEN : 88.66 (-0.26%)
FREQ : 14.9800 (+5.94%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DEN : 88.66 (-0.26%)
NLTX : 13.96 (+1.45%)
FREQ : 14.9800 (+5.94%)
Why Did Bullfrog AI Stock Jump More Than 50%?

Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.

BFRG : 3.02 (+3.42%)
SHPH : 0.3920 (-2.34%)
FREQ : 14.9800 (+5.94%)
NLSP : 0.1372 (+3.39%)
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates...

FREQ : 14.9800 (+5.94%)
Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim...

FREQ : 14.9800 (+5.94%)
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results...

FREQ : 14.9800 (+5.94%)
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced...

FREQ : 14.9800 (+5.94%)
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced...

FREQ : 14.9800 (+5.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Frequency Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company's lead product candidate, FX-322, is in clinical development and is designed to regenerate...

See More

Key Turning Points

3rd Resistance Point 0.3596
2nd Resistance Point 0.3398
1st Resistance Point 0.3197
Last Price 14.9800
1st Support Level 0.2798
2nd Support Level 0.2600
3rd Support Level 0.2399

See More

Last Price 14.9800
52-Week High 5.5900
Fibonacci 61.8% 3.5245
Fibonacci 50% 2.8865
Fibonacci 38.2% 2.2485
52-Week Low 0.1830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar